Related Experiment Video
Updated: Mar 2, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line
Beate Rinner1, Greta Gandolfi2, Katharina Meditz3
1Division of Biomedical Research, Medical University Graz, Graz, Austria. beate.rinner@medunigraz.at.
Abstract:
NRAS mutation in melanoma has been associated with aggressive tumor biology and poor prognosis. Although targeted therapy has been tested for NRAS mutated melanoma, response rates still appear much weaker, than in BRAF mutated melanoma. While plenty of cell lines exist, however, only few melanogenic cell lines retain their in vivo characteristics. In this work we present an intensively pigmented and well-characterized cell line derived from a highly aggressive NRAS mutated cutaneous melanoma, named MUG-Mel2. We present the clinical course, unique morphology, angiogenic properties, growth characteristics using in vivo experiments and 3D cell culture, and results of the exome gene sequencing of an intensively pigmented melanogenic cell line MUG-Mel2, derived from a cutaneous metastasis of an aggressive NRAS p. Q61R mutated melanoma. Amongst several genetic alterations, mutations in GRIN2A, CREBP, PIK3C2G, ATM, and ATR were present. These mutations, known to reinforce DNA repair problems in melanoma, might serve as potential treatment targets. The aggressive and fast growing behavior in animal models and the obtained phenotype in 3D culture reveal a perfect model for research in the field of NRAS mutated melanoma.
Insights
A new cell line, MUG-Mel2, derived from aggressive NRAS-mutated melanoma, offers a valuable model for studying this challenging cancer. Its unique characteristics and genetic alterations provide potential new treatment targets for NRAS-mutated melanoma.
Area of Science:
- * Oncology
- * Dermatology
- * Molecular Biology
Background:
- * NRAS mutations in melanoma are linked to aggressive disease and poor outcomes.
- * Current targeted therapies for NRAS-mutated melanoma show limited efficacy compared to BRAF-mutated melanoma.
- * Few available melanogenic cell lines accurately reflect in vivo characteristics of NRAS-mutated melanoma.
Purpose of the Study:
- * To introduce and characterize a novel, intensively pigmented melanogenic cell line, MUG-Mel2.
- * To evaluate MUG-Mel2 as a preclinical model for aggressive NRAS-mutated cutaneous melanoma.
- * To identify potential therapeutic targets within the genetic landscape of MUG-Mel2.
Main Methods:
- * Characterization of MUG-Mel2 cell line, including morphology, pigmentation, and angiogenic properties.
- * In vivo experiments and 3D cell culture to assess growth characteristics.
- * Exome gene sequencing to identify genetic alterations.
Main Results:
- * MUG-Mel2 is a well-characterized, intensively pigmented cell line derived from aggressive NRAS p.Q61R mutated cutaneous melanoma.
- * The cell line exhibits aggressive and fast-growing behavior in animal models and distinct phenotypes in 3D culture.
- * Exome sequencing revealed mutations in GRIN2A, CREBP, PIK3C2G, ATM, and ATR, potentially impacting DNA repair.
Conclusions:
- * MUG-Mel2 serves as a robust and relevant preclinical model for NRAS-mutated melanoma research.
- * Identified mutations suggest potential therapeutic strategies targeting DNA repair pathways.
- * This cell line facilitates the study of aggressive melanoma biology and the development of novel treatments.
